News at CenExel

FDA Approves ABRYSVO for RSV

In the last week, the FDA approved the first maternal vaccine designed to safeguard infants from respiratory syncytial virus (RSV) during the critical period immediately from birth up to 6 months of age, when they are most vulnerable to infection. RSV, a highly...

Evaluation of mRNA-1273 Vaccine in Children

CenExel is proud to announce the publication of the work of Kimball A. Johnson, MD, from CenExel iResearch, in the New England Journal of Medicine. Dr. Johnson participated in a study of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. Other contributors included Evan J. Anderson, MD, C. Buddy Creech, MD, MPH, Vlasimir Berthaud, MD, MPH, Arin Piramzadian, DO, et al., for the KidCOVE Study Froup*